Literature DB >> 29023674

Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response.

Deanna J Brackman1, Kathleen M Giacomini1,2.   

Abstract

Reverse translational research takes a bedside-to-bench approach, using sophisticated basic research to explain the biological mechanisms behind observed clinical data. For transporters, which play a role in human disease and drug response, this approach offers a distinct advantage over the typical translational research, which often falters due to inadequate in vitro and preclinical animal models. Research on ABCG2, which encodes the Breast Cancer Resistance Protein, has benefited immensely from a reverse translational approach due to its broad implications for disease susceptibility and both therapeutic and adverse drug response. In this review, we describe the success of reverse translational research for ABCG2 and opportunities for further studies.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29023674      PMCID: PMC5760319          DOI: 10.1002/cpt.903

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  68 in total

Review 1.  From idea to market: the drug approval process.

Authors:  M S Lipsky; L K Sharp
Journal:  J Am Board Fam Pract       Date:  2001 Sep-Oct

2.  ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

Authors:  J E Keskitalo; O Zolk; M F Fromm; K J Kurkinen; P J Neuvonen; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2009-05-27       Impact factor: 6.875

3.  Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Authors:  Federico Innocenti; Richard L Schilsky; Jacqueline Ramírez; Linda Janisch; Samir Undevia; Larry K House; Soma Das; Kehua Wu; Michelle Turcich; Robert Marsh; Theodore Karrison; Michael L Maitland; Ravi Salgia; Mark J Ratain
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

Review 4.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

Review 5.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

Review 6.  Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).

Authors:  Hannah H Lee; Richard H Ho
Journal:  Br J Clin Pharmacol       Date:  2017-01-19       Impact factor: 4.335

7.  Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.

Authors:  Ai Tamura; Kanako Wakabayashi; Yuko Onishi; Misako Takeda; Yoji Ikegami; Seigo Sawada; Masahisa Tsuji; Yoichi Matsuda; Toshihisa Ishikawa
Journal:  Cancer Sci       Date:  2007-02       Impact factor: 6.716

8.  Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.

Authors:  Kiyotaka Yoh; Genichiro Ishii; Tomoyuki Yokose; Yuji Minegishi; Kohji Tsuta; Koichi Goto; Yutaka Nishiwaki; Tetsuro Kodama; Moritaka Suga; Atsushi Ochiai
Journal:  Clin Cancer Res       Date:  2004-03-01       Impact factor: 12.531

9.  The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.

Authors:  Tomoyuki Mizuno; Masahide Fukudo; Tsuyoshi Fukuda; Tomohiro Terada; Min Dong; Tomomi Kamba; Toshinari Yamasaki; Osamu Ogawa; Toshiya Katsura; Ken-Ichi Inui; Alexander A Vinks; Kazuo Matsubara
Journal:  Ther Drug Monit       Date:  2014-06       Impact factor: 3.681

10.  A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group.

Authors:  R Milroy
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

View more
  11 in total

Review 1.  Scientific considerations for global drug development.

Authors:  Jennifer L Wilson; Kit Wun Kathy Cheung; Lawrence Lin; Elizabeth A E Green; Analia I Porrás; Ling Zou; David Mukanga; Paul A Akpa; Delese Mimi Darko; Rae Yuan; Sheng Ding; Wiltshire C N Johnson; Howard A Lee; Emer Cooke; Carl C Peck; Steven E Kern; Dan Hartman; Yoshikazu Hayashi; Peter W Marks; Russ B Altman; Murray M Lumpkin; Kathleen M Giacomini; Terrence F Blaschke
Journal:  Sci Transl Med       Date:  2020-07-29       Impact factor: 17.956

Review 2.  Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation.

Authors:  Camille Tron; Florian Lemaitre; Céline Verstuyft; Antoine Petitcollin; Marie-Clémence Verdier; Eric Bellissant
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

3.  Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.

Authors:  Xiao Liang; Yudi Wang; Hui Shi; Mengmeng Dong; Haobo Han; Quanshun Li
Journal:  Int J Nanomedicine       Date:  2021-03-30

4.  A Comprehensive Analysis of Ontogeny of Renal Drug Transporters: mRNA Analyses, Quantitative Proteomics, and Localization.

Authors:  Kit Wun Kathy Cheung; Bianca D van Groen; Edwin Spaans; Marjolein D van Borselen; Adrianus C J M de Bruijn; Ytje Simons-Oosterhuis; Dick Tibboel; Janneke N Samsom; Robert M Verdijk; Bart Smeets; Lei Zhang; Shiew-Mei Huang; Kathleen M Giacomini; Saskia N de Wildt
Journal:  Clin Pharmacol Ther       Date:  2019-07-03       Impact factor: 6.875

5.  Identification of Functional Transcriptional Binding Sites within Chicken Abcg2 Gene Promoter and Screening Its Regulators.

Authors:  Yujuan Zhang; Jinhu Huang; Xiangxiu Li; Ci Fang; Liping Wang
Journal:  Genes (Basel)       Date:  2020-02-10       Impact factor: 4.096

6.  QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats.

Authors:  Congyang Ding; Yajing Li; Xiao Li; Lu Meng; Ran Fu; Xiaonan Wang; Ying Li; Yinling Ma; Zhanjun Dong
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.503

Review 7.  Model-informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets.

Authors:  Alain Munafo; Nadia Terranova; Dandan Li; Ping Liu; Karthik Venkatakrishnan
Journal:  Clin Transl Sci       Date:  2021-10-26       Impact factor: 4.689

8.  Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer.

Authors:  Keqiang Zhang; Jinhui Wang; Lu Yang; Yate-Ching Yuan; Tommy R Tong; Jun Wu; Xinwei Yun; Melissa Bonner; Rajendra Pangeni; Zheng Liu; Tiger Yuchi; Jae Y Kim; Dan J Raz
Journal:  Mol Cancer       Date:  2018-10-22       Impact factor: 27.401

9.  The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP.

Authors:  Sophie E B Ambjørner; Michael Wiese; Sebastian Christoph Köhler; Joen Svindt; Xamuel Loft Lund; Michael Gajhede; Lasse Saaby; Birger Brodin; Steffen Rump; Henning Weigt; Nils Brünner; Jan Stenvang
Journal:  Cells       Date:  2020-03-04       Impact factor: 6.600

10.  Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.

Authors:  Bianca Vora; Deanna J Brackman; Ling Zou; Maria Garcia-Cremades; Marina Sirota; Radojka M Savic; Kathleen M Giacomini
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.